Ginkgo Bioworks Holdings, Inc. (DNA) Stock & Financials
Data as of (545 days ago)|Source: SEC EDGAR
Ginkgo Bioworks Holdings, Inc. (DNA) is a biotechnology company. The company reports annual revenue of $181M and net loss of $340M.
What to check next
For informational purposes only. Not investment advice. Data may be delayed or inaccurate; verify independently. The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results. Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing.
Ginkgo Bioworks Holdings, Inc. Key Financials(TTM Est.)
Data from SEC EDGAR filings. TTM = Trailing Twelve Months.
Ginkgo Bioworks Holdings, Inc. Financial Health ScoreFY2025
Weak financial health; requires careful evaluation
-3 pts YoYThis Financial Health Score is a proprietary metric calculated from SEC EDGAR filings for educational and informational purposes only. It does not constitute investment advice or a recommendation to buy or sell any security. Results vary significantly by industry. Conduct your own research before making investment decisions.
Data Highlights
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
5-Year Revenue & Net Income Trend
Chart shows fiscal year data from SEC EDGAR filings. Hover over data points for details.
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
About Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.
- Industry
- Biotechnology
Valuation
Valuation Data UnavailablePrice-based valuation metrics (P/E, P/B) require real-time stock price data which is not included in SEC filings.
Benjamin Graham: Graham recommended P/E ratio not exceed 15 for reasonable valuation. Understanding valuation metrics
Profitability
Profitability Data Under Review* Some quarterly data is missing. Values are calculated based on annual report figures.
Profitability metrics are being verified. Some SEC filing data may require additional validation.
Warren Buffett: Buffett looks for consistent ROE above 20% as a sign of competitive advantage. How to evaluate profitability
Financial Health
Balance Sheet Data LimitedInsufficient data to assess financial health.
Peter Lynch: Lynch: normal balance sheet has 75% equity, 25% debt. Understanding financial health
Dividend
Dividend Data UnavailableDividend yield data is not available from SEC filings. Check the company's investor relations page for dividend information.
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
Ginkgo Bioworks Holdings, Inc. 7-Year Revenue, Profit & Cash Flow History
Revenue has grown at a 21.0% CAGR over the past 6 years.
Annual Financials
FY2025 - FY2019| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $170.2M(-25.1%) | $227.0M(-9.7%) | $251.5M(-47.4%) | $477.7M(+52.2%) | $313.8M(+309.4%) | $76.7M(+41.5%) | $54.2M |
| Net Income | $-312,763,000(+42.8%) | $-547,029,000(+38.7%) | $-892,869,000(+57.6%) | $-2,104,929,000(-15.0%) | $-1,830,047,000(-1345.4%) | $-126,609,000(-6.1%) | $-119,327,000 |
| Total Assets | $1.1B | $1.4B | $1.7B | $2.5B | $2.1B | $675.2M | - |
| Total Debt | - | - | - | - | - | - | - |
| Total Equity | $508.6M | $716.1M | $1.1B | $1.7B | $1.5B | $470.1M | $501.9M |
| Profit Margin | -183.8% | -240.9% | -355.1% | -440.6% | -583.1% | -165.2% | - |
| ROE | -61.5% | -76.4% | -81.4% | -121.2% | -121.6% | -26.9% | -23.8% |
| ROA | -27.9% | -39.7% | -53.6% | -82.9% | -88.4% | -18.8% | - |
Quarterly Financials
Last 8 quarters| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $38.8M | $49.6M | $48.3M | $89.0M | $56.2M | $37.9M | $55.4M | $80.6M |
| Net Income | $-80,755,000 | $-60,300,000 | $-90,957,000 | $-56,403,000 | $-217,181,000 | $-165,911,000 | $-302,891,000 | $-173,315,000 |
| Total Assets | $1.2B | $1.2B | $1.3B | $1.5B | $1.6B | $1.6B | $2.0B | $2.3B |
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
Insider Trading
Source: SEC EDGAR Form 4 filings. Only purchase (P) and sale (S) transactions shown.
Ginkgo Bioworks Holdings, Inc. Free Cash Flow & Dividend Coverage
Cash Flow History
FY2019 - FY2025| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Operating CF | -$44.7M | -$135.8M | -$253.8M | -$252.2M | -$295.5M | -$319.6M | -$171.1M |
| CapEx | -$22.2M | -$57.8M | -$56.5M | -$52.3M | -$40.8M | -$62.5M | -$7.7M |
| Free Cash Flow | -$66.9M | -$193.7M | -$310.3M | -$304.5M | -$336.3M | -$382.1M | -$178.7M |
| FCF Margin | - | - | -98.9% | -63.7% | -133.7% | -168.3% | -105.0% |
Source: SEC EDGAR 10-K filings. FCF = Operating Cash Flow - Capital Expenditures. Free cash flow guide
As of FY2025 · SEC 10-K Annual Filings · Updated Feb 28, 2026
Ginkgo Bioworks Holdings, Inc. Risk Factors
Company-disclosed SEC risk factors
Risk factors are disclosed by the company in its SEC Form 10-K, Item 1A. Billiver does not classify or summarize company-specific legal, operational, financial, or market risks here.
Sector context: Health Care. This is not a Billiver risk assessment for DNA.
Source note: the SEC Form 10-K includes Item 1A, "Risk Factors." The full risk-factor text should be read from the company’s own SEC filing.
Ginkgo Bioworks Holdings, Inc. FAQ
What is Ginkgo Bioworks Holdings, Inc.'s annual revenue?
Ginkgo Bioworks Holdings, Inc. (DNA) reported $181 million in trailing twelve-month (TTM) revenue. This financial data is compiled from SEC EDGAR 10-K filings.
Does Ginkgo Bioworks Holdings, Inc. pay dividends?
No, Ginkgo Bioworks Holdings, Inc. (DNA) does not currently pay dividends to shareholders.
What is Ginkgo Bioworks Holdings, Inc.'s financial health score?
Ginkgo Bioworks Holdings, Inc. has a financial health score of 25/100 (Grade: F), evaluating profitability, solvency, liquidity, and growth based on SEC EDGAR data.
How many years of Ginkgo Bioworks Holdings, Inc. financial data are available?
7 years of financial data are available for Ginkgo Bioworks Holdings, Inc. from FY2019 to FY2025. All figures are compiled from SEC EDGAR 10-K filings.